To learn more about ongoing research into COVID-19 treatments, go to https://combatcovid.hhs.gov/clinicaltrials
The ACTIV-6 protocol will explore a pool of up to seven drugs approved by FDA for other conditions—an approach called drug repurposing—and test their safety and effectiveness in treating mild to moderate COVID-19. Because the drugs under consideration already have been tested in humans, repurposing could deliver COVID-19 treatment options sooner. Drugs will be administered orally or by inhaler and will be easy for participants to take at home. Participants will be assigned randomly to receive either a placebo or one of the treatments, which will be sent to them by mail. Enrollment is expected to open in a few weeks to up to 13,500 participants who are at least 30 years old, have tested positive for SARS-CoV-2 infection, and have experienced two or more mild to moderate symptoms of COVID-19 for no more than 7 days. Researchers plan to assess changes in patients’ symptoms over a 14-day period, as well as hospitalizations and deaths over a 28-day period. They also will assess long-term COVID-19-related symptoms at 90 days after treatment begins. Aims to provide evidence-based treatment options for many adult patients with COVID-19 who have mild to moderate symptoms and are not sick enough to be hospitalized.
This project is funded by a grant from the National Institutes of Health (NIH) and National Center for Advancing Translational Sciences (NCATS) (award number UL1-TR002535-03S3).